ABSTRACT Background: Açai (Euterpe oleracea) is a polyphenol-rich fruit marketed as beneficial for health. Experimental data showing improvements in health markers arising from açai consumption in humans is limited. Objective: The objective of the present study was to investigate the effect of açai consumption on acute changes in vascular function and on other disease risk markers, including postprandial plasma insulin, glucose, and oxidative stress. Design: Twenty-three healthy male volunteers, aged 30-65 y and with a body mass index (in kg/m 2 ) of 25-30, completed a randomized, controlled, high-fat challenge, double-blind, crossover, acute dietary intervention trial. The volunteers consumed either an açai-based smoothie (AS) or a macronutrient-matched control smoothie (PS) together with a high-fat breakfast meal challenge. The primary endpoint was the assessment of endothelial function in the brachial artery by flow-mediated dilatation (FMD). Results: The acute consumption of an AS containing 694 mg total phenolics improved vascular function, with postprandial increases in FMD from baseline of 1.4% at 2 h compared with 0.4% after consumption of the PS (P = 0.001) and increases at 6 h of 0.8% for the AS compared with 20.3% for the PS (P , 0.001). There was also a significantly lower incremental area under the curve (iAUC) for total peroxide oxidative status after açai consumption relative to the control. No significant changes were observed in blood pressure, heart rate, or postprandial glucose response. However, the first postprandial insulin peak (after breakfast) and the iAUC for insulin were elevated for the AS relative to the PS. Conclusions: In this acute study in overweight men, açai consumption was associated with improvements in vascular function, which may lower the risk of a cardiovascular event. Future intervention studies, perhaps with a chronic design, in wider populations and with other biomarkers of disease risk are needed to fully elucidate the benefits of açai to health. This trial was registered at clinicaltrials. gov as NCT02292329.
INTRODUCTION
Dietary practices that reduce the burden of cardiovascular diseases (CVDs) 3 are a desirable goal of public health programs.
Prospective cohort studies strongly suggest that a diet high in fruit and vegetables may protect against CVD (1, 2) . There is, however, a need to identify individual plant foods with strong protective effects and to better understand the mechanisms involved in food-mediated disease prevention (3) . Polyphenols are widely studied, nonnutritive bioactive compounds found in plant foods; these compounds have a well-characterized free-radical scavenging ability in vitro, which may decrease oxidative stress in vivo (4) . Polyphenols may also improve endothelial function, lower blood pressure (BP) (5, 6) , improve insulin sensitivity (7), decrease LDL-cholesterol concentrations (8) , and modulate inflammatory response (9) . Dietary interventions with polyphenolrich berries induce improvements in risk factors associated with metabolic syndrome, diabetes, and CVD (10, 11) . The flow-mediated dilatation (FMD) method is a measure of arterial endothelial dysfunction and a well-established early biomarker of CVD risk (12) . Dietary interventions with blueberry have been shown to reverse this endothelial dysfunction, at least in an acute setting, in which changes in the concentration of phenolic metabolites in plasma were associated with observed postprandial improvements in FMD (13) . This suggests that polyphenols present in blueberries may mediate a beneficial effect on FMD. Several other dietary intervention studies with polyphenol-rich foods, including, for example, cocoa (14) , green tea (15) and grapes (16) , reported similar improvements in FMD when test foods were consumed in an acute setting.
The açai fruit (Euterpe oleracea Mart., Arecaceae) is notable for its very high concentration of flavonoids; this suggests that potential health benefits from its consumption may exist. The food media have picked up on this, despite a paucity of supporting human intervention study data. Açai has subsequently found its way into the global health food market (17, 18) . In the United Kingdom, the consumption of açai remains very low. It is available as a powdered supplement or as a minor constituent of foodstuffs, such as in mixed berry drinks or yogurts, and these are often marketed with unsubstantiated health claims. Some characterization of potential benefits from consumption of açai is therefore necessary to better inform the consumer and to establish appropriate dietary recommendations for the prevention of disease (19) .
To our knowledge, the effects of açai on arterial endothelial dysfunction have not been assessed. Here, we describe results from a double-blind, controlled intervention trial with açai consumed as a smoothie blended with banana, as it is typically prepared in Brazil, and with FMD as the primary endpoint. We hypothesized that the consumption of açai, together with a highfat breakfast intervention, would ameliorate the detrimental vascular response to that high-fat intervention and induce improvements in other cardiovascular and metabolic disease risk markers in an acute setting.
METHODS

Materials
Frozen açai pulp was donated by Sublime Foods Company Ltd. Fresh banana was purchased locally. Flavonoid and phenolic acid standards were obtained from Sigma-Aldrich Co. Ltd. or Extrasynthese. Water, methanol, and acetonitrile (HPLC grade) were purchased from Fisher Scientific. Glucose concentrations were quantified by using an iLAB 600 biochemical analyzer (Instrumentation Laboratory) with enzymatic colorimetric and standard kits with appropriate seronormal, low-and high-quality-control standards supplied by Instrumentation Laboratory and Alpha Laboratories (IL Test TM Glucose). Serum insulin was determined with an enzyme immunoassay by using reagents supplied by Dako Cytomation and a GENios plate reader (Tecan Group). Blood tubes for serum and plasma were supplied by Geriner BioOne Ltd. All other chemicals and reagents were obtained from Sigma-Aldrich Co. Ltd. or Fisher Scientific.
Intervention study subjects
Twenty-three male volunteers were recruited from the University of Reading and the surrounding area through the Hugh Sinclair Unit of Human Nutrition volunteer database and through advertisements within the local community between September 2014 and January 2015. Volunteers were required to be of good general health but with a BMI (in kg/m 2 ) of 25-30, which is associated with a slight increase in the risk of developing metabolic disease. The inclusion criteria were as follows: male, aged 30-65 y, nonsmoker, and total cholesterol ,8.0 mmol/mL. Volunteers were excluded if they suffered from diabetes, anemia, or cardiovascular, renal, gastrointestinal, or hepatic disease; if they were being medicated for hyperlipidemia, hypertension, inflammation, or depression; or if they were on a weightreduction program or were taking any nutritional supplements. Of the first 37 men screened, 24 were recruited and randomly assigned to the crossover study arms; 23 participants completed the study with 1 dropout due to a change in his personal circumstances ( Figure 1 ).
Study design and treatments
The study was registered as a clinical trial (clinical trials.gov ID: NCT02292329) and was conducted according to the Declaration of Helsinki and followed Good Clinical Practice. It was given a favorable ethical opinion for conduct by the University of Reading Research Ethics Committee (ethics reference number 13/51). The study was an acute randomized, controlled, doubleblind crossover study with an açai smoothie (AS; study treatment). The volunteers were randomly assigned by using a minimization program (https://www-users.york.ac.uk/~mb55/guide/minim.htm) by the researcher to generate the randomization sequence (with discrimination for age and BMI) for the treatment arms. Açai is very rarely consumed in this format in the United Kingdom and it was unfamiliar to the participants, which enabled us to effectively blind them to the treatment arm.
For the AS, frozen açai pulp (150 g) was prepared in a smoothie with 50 g banana and no other additives. An analysis of the nutritional profile of both smoothies is shown in Participants were given dietary advice to avoid the consumption of polyphenol-rich foods for $24 h before the study visits, and each volunteer was asked to consume a standard low-flavonoid evening meal containing ,15 g fat and ,7 g saturated fat and to fast overnight (12 h thereafter) before the intervention. A 24-h dietary recall was also taken at each visit (Supplemental Table 1 ). The study visit began at 0800. Participants rested in the unit for 30 min before measurements of baseline BP and FMD. Blood (18 mL) was then collected via a cannula inserted into the antecubital vein of the forearm (the study procedure is shown in Supplemental Figure 1 ). Volunteers were then provided with a high-fat challenge breakfast (50 g fat) (Supplemental Table 2 ) and asked to consume the smoothie with the breakfast within a 10-min total time frame. An independent researcher who was unaware of the study arm collected blood samples at regular intervals for 7 h (1-7 h) and performed vascular measurements at 2, 4, and 6 h. A second lunchtime standard moderate-fat (14.2 g fat) meal was provided after the collection of the fourth-hour blood samples (Supplemental Figure 1) . Urine samples were collected at baseline and at 0-7 and 7-24 h. Participants were given a standard low-polyphenol evening meal at the end of the visit day to ensure phenolics recovered in the 24-h urine samples were from açai.
Assessment of the polyphenol content of test foods
ASs were prepared as described above. Samples of both AS and PS were taken and freeze-dried. Flavonoids and phenolic acids were extracted by using acidified methanol with 0.1% formic acid for the anthocyanin compounds and methanol:water (80:20, vol:vol) for other phenols. The polyphenols were characterized by using a method previously validated by our group (20) . HPLC was performed by using an Agilent 1100 series liquid chromatograph with a quaternary pump and a photodiode array detector (Hewlett-Packard Agilent). A Nova Pak C18 4-mm column (4.6 3 250 mm; Waters) was used to separate the phenolic constituents at a solvent flow rate of 0.4 mL/min, and the column was allowed to equilibrate for 15 min between each injection. At least 50 mL of each sample or standard solution was injected for each analysis. The mobile phase A was 95% HPLC water, 5% methanol, and 0.1% HCl; mobile phase B was 50% HPLC water, 50% acetonitrile, and 0.1% HCl. The identification of phenolic compounds from açai was based on the mass spectra fragmentation patterns and retention times in the UV spectra compared to standards selected on the basis of previous literature (17) . The detection wavelengths were 254, 280, 320, and 520 nm. A standard curve was constructed to quantify the amount of each compound identified in the AS (20) .
Nitrite and nitrate in test foods
Nitrite and nitrate were assessed in aqueous extracts of test foods by using the ENO-30, HPLC-based approach (Eicom, San Diego, CA). Briefly, smoothies were prepared and mixed with distilled low-nitrite and -nitrate water (50:50). Samples were centrifuged at 3000 3 g for 10 min at 48C, and the supernatant passed through a 0.45-mM syringe filter. A total of 200 mL was collected and 10 mL was immediately injected into the ENO-30 system. Calibration curves for nitrite and nitrate were prepared by using NaNO 2 and NaNO 3 standards in pure water. Carrier solution was prepared by using pure water (900 mL) with methanol (100 mL) and carrier powder (obtained from Eicom). Mobile phase A was prepared with pure water (450 mL), 100 mL methanol, 12.5 mL concentrated hydrochloric acid (35-57%), and reactor A powder (obtained from Eicom). Mobile phase B was prepared from pure water (450 mL) and 100 mL of methanol and reactor B powder (obtained from Eicom). Solutions A and B were mixed in a ratio of 1:1. Separation was achieved by using a NO-PAK column size 4.6 and 50 mm (Eicom) and a flow rate of 100 mL/min. Pump pressures were 300 and 100 mL/min for mobile phases A and B, respectively.
Vascular function and measurements
FMD
FMD of the brachial artery was the primary endpoint measure of the study and was measured according to standard guidelines (21) by using an ALT Ultrasound HDI-15000 system (ATL Ultrasound) in combination with a semiautomated computerized analysis system (Brachial Analyzer; Medical Imaging Applications). Briefly, after a 30-min rest in the supine position in a quiet, temperature-controlled room (228-248C), a baseline vascular measurement was taken. Vascular measurements were taken at 2, 4, and 6 h after the meal. The brachial artery was imaged longitudinally at 2-10 cm proximal to the antecubital fossa. After baseline images were recorded over 60 s, a BP cuff placed around the forearm was inflated to 220 mm Hg. Then, after 5 min of occlusion, the BP cuff was rapidly released to allow reactive hyperemia, with image collection that continued for 5 min after release. A single researcher who was blinded to the intervention analyzed all image files. The peak diameter was defined as the largest diameter obtained after the cuff was released. The FMD percentage was calculated as the relative diameter change from the baseline compared with the peak diastolic diameter.
BP measurements
Systolic BP, diastolic BP, and heart rate were measured in all of the participants at baseline and at 2, 4, and 6 h after the meal. Before measurement, participants rested for 30 min, and the mean of triplicate measurements was recorded with an OMRON-M6 automatic digital (HEM-7211-E8) Comfort Upper-Arm Blood Pressure Monitor.
Biochemical analysis
Plasma blood samples were coated in VACUETTE EDTAcoated Vacutainers (Greiner BioOne Ltd.) and kept on ice until centrifugation at 1600 3 g for 15 min at 48C. Vacutainer rapid serum separator tubes (BD, USA) were used to collect blood and left at room temperature for 30 min to allow for clot formation, then centrifuged at 1600 3 g for 15 min at room temperature to isolate serum. Urine samples were collected at different time points (0-7 and 7-24 h), the total volume of urine produced at each time point was recorded, and aliquots were prepared for storage after centrifugation at 1600 3 g for 10 min at 48C. Blood and urine samples were stored at 2808C until further analysis. Serum lipids were measured at baseline via the iLAB 600, and LDL cholesterol was calculated by using the Friedewald equation. Total serum glucose and insulin were analyzed at all time points (0, 1, 2, 3, 4, 5, 6 , and 7 h) by using an ILAB600 auto-analyser (Instrumentation Laboratory, USA). Serum insulin concentrations at each time point were analyzed by using an ELISA.
Total oxidant capacity
Total oxidant capacity (TOC) in plasma was assessed as a measure of total peroxide concentrations according to the method of Tatzber et al. (22) . Briefly, 10 mL standards [0, 0.125, 0.25, 0.5, and 1 mmol/L of hydrogen peroxide (30%)] or plasma samples were added to the wells of a 96-well plate, followed by the addition of 200 mL reaction mixture. The stock reaction mixture (prepared fresh) contained 20 mL reaction buffer (phosphate-citrate: 0.05 M, pH 5.0), 20 mL substrate solution (3,3#,5,5#-tetramethylbenzidine solution at 1 mg/mL in DMSO), and 20 mL peroxidase solution (10 mg/mL in 0.1 M phosphate buffer, pH 6.0). The 96-well plate was incubated for 20 min on ice, and the reaction was then stopped by the addition 2 M sulfuric acid. Absorbance was measured immediately at a wavelength of 450 nm on a GENios plate reader (Tecan, Switzerland) at room temperature with Magellan software (Tecan).
Statistical analysis and power calculations
Power calculations were based on the primary endpoint, change in FMD from baseline to 2 h, with a required sample size estimated on the basis of the variance of repeated measurements in the control group and on control data. On the basis of previous acute studies of the effects of flavonoid-rich foods on FMD and aiming for significant improvement in FMD of between 1.5% and 2%, with a baseline vasodilatation of 10%, 23 participants were required to achieve a study power of 80% with an a of 0.05. Results are expressed as means 6 SEMs. Data were checked for normal distribution. Two-factor repeated-measures ANOVA was used to analyze the data for FMD, BP, and 7-h postprandial glucose, insulin, and plasma TOC after the 2 treatments.
The incremental AUC (iAUC) over 7 h was calculated for insulin, glucose, and TOC by using the trapezoidal method excluding the area below fasting level (23) . The timings of the maximum concentration (MaxC) of serum glucose and insulin after each meal were calculated [time to maximum concentration (Tmax) 1-4 h and Tmax 4-7 h ] and used in the analysis by pairedsamples t test. All of the statistical analyses were performed by using SPSS software (version 18).
RESULTS
Baseline characteristics of the study participants
Baseline characteristics of the study population are summarized in Table 2 . The enrolled participants were men at a slightly elevated risk of metabolic syndrome, with a BMI in the overweight category and a mean 6 SEM age of 46 6 1.9 y. At screening, participants had a waist circumference of 97.6 6 1.6 cm and serum lipids within the normal range ( Table 2 ). The participants were normoglycemic and test results for hemoglobin and for liver function showed no evidence of ill health. BP (systolic and diastolic BP) and heart rate were also within the acceptable healthy range. No side effects were reported by the study participants.
Polyphenol content of smoothies
The polyphenol and phenolic acid content of the AS was 694 mg (Table 1 ). Its total anthocyanin content was 493 mg (principally, cyanidin-3-O-glucoside, cyanidin-3-O-rutinoside, pelargonidin-3-O-glucoside, and peonidin-3-O-rutinoside), the quercetin content was 9.6 mg, and gallic acid content was 173.6 mg. Small amounts of some phenolic acids, such as caffeic acid, ferulic acid, vanillic acid, 3,4-dihydroxybenzoic acid, 4-hydroxybenzoic acid, and 2,5-dihydroxybenzoic acid, were also identified and quantified in the AS ( Table 1 ). The polyphenol content of the PS was below the level of detection (,10 mg).
Vascular function
FMD changed from baseline over the course of the study day (2-factor ANOVA, time effect; P = 0.028), peaking 2 h after the test meal was consumed and again at 6 h ( Figure 2) . Moreover, there was a highly significant treatment effect on FMD for the AS relative to the PS (2-factor ANOVA, treatment effect; P , 0.001). However, the time-by-treatment interaction was not significant (P = 0.2).
The primary endpoint for this study was the change from baseline in FMD at 2 h. The magnitude of increase in FMD from baseline after consumption of the AS was 1.4% 6 0.6% (P = 0.034, t test), with only a 0.4% 6 0.6% (P = 0.52) increase FIGURE 2 FMD after consumption of an AS containing 694 mg polyphenols or a macronutrient-matched PS (n = 23). Values are means 6 SEMs. Data were analyzed by using a 2-factor repeated-measures ANOVA with time and treatment as the 2 factors (significant effect of time, P = 0.03; significant effect of treatment, P # 0.001). At baseline, the treatment arms were not significantly different (P = 0.31). There was no significant interaction of time by treatment (P = 0.2), reflecting the similar, but much attenuated, pattern of FMD measures throughout the day in the PS relative to the AS. AS, açai smoothie; FMD, flow-mediated dilatation; PS, control smoothie. after consumption of the PS. The difference in the change in FMD from baseline for the AS relative to the PS at 2 h was also significant (P = 0.001, t test). After 4 h, the FMD measurements for the açai group had dropped to a 0.2% 6 0.5% increase above baseline, whereas the control fell to 20.5% 6 0.7% below that of baseline levels. The difference in the change in FMD from baseline for the AS relative to the PS at 4 h was also significant (P = 0.003, t test). A second peak in FMD was observed at 6 h postintervention with the AS, to 0.8% 6 0.7%, whereas FMD after the consumption of the PS remained slightly below baseline (20.3% 6 0.5%). The difference in the change in FMD from baseline for the AS relative to the PS at 6 h was also significant (P , 0.000, t test) (Figure 2 ). No significant differences in systolic BP, diastolic BP, or heart rate were observed between the treatment groups over the course of the study day ( Table 3) .
Postprandial glucose and insulin response
As expected, the consumption of the breakfast resulted in a rapid increase in serum glucose concentration, peaking, on average, at 1 h (5.90 6 0.23 mmol/L with the AS and 5.28 6 0.27 mmol/L with the PS) and then returning to baseline between 2 and 4 h ( Figure 3A) . After consumption of the lunch, serum glucose concentrations again increased, reaching a higher maximum (7.49 6 0.24 mmol/L with the AS and 6.75 6 0.29 mmol/L with the PS) than after breakfast. No significant differences in the iAUC for serum glucose were observed between the 2 treatments, and no time-by-treatment interaction was observed (P = 0.38) ( Figure 3B ). The postprandial serum insulin response to the sequential mixed meals is shown in Table 4 . Significant treatment (P = 0.02) and time (P , 0.001) effects were observed. The AS induced a significantly higher maximum insulin concentration (maxC 1-4 h ; P = 0.009) than the PS, and significant differences were found in the iAUC (P = 0.003). However, no time (h)-by-treatment interaction was observed (P = 0.15).
TOC
The postprandial plasma TOC over 7 h after the consumption of the AS or the PS is shown in Figure 3C . The iAUC over the 7-h study period showed significantly lower plasma TOC for the AS relative to the PS (P = 0.02) ( Table 4) . No significant differences were observed at any individual sampling time point over this period and the time (h)-by-treatment interaction was P = 0.68.
DISCUSSION
To our knowledge, this is the first human study that shows the effects of consuming açai with a high-fat breakfast on vascular function and other metabolic disease risk markers in an acute setting. We hypothesized that the consumption of açai would ameliorate the detrimental vascular response to a high-fat meal and induce improvements in other cardiovascular and metabolic disease risk markers in an acute setting. Our study shows that açai induces clinically meaningful improvements in vascular function (FMD) in overweight individuals (a 1.4% increase at 2 h). At a population level, a 1% increase in FMD is associated with a 13% reduction in risk of a cardiovascular event (24) .
We speculate that the polyphenols present in the açai were responsible for these changes in vascular function. No time-bytreatment effects were observed in FMD after the consumption of the AS compared with the PS over the 6-h intervention window. A comparison of the composition of the açai compared with the control food showed that the PS was matched to within 1% for energy and for fiber, to within 10% for carbohydrate, and to within 20% for total fat. The PS had a slightly higher nitrate content but a lower nitrite content; the total content of nitrite and nitrate in the PS was double that of the AS. In contrast, the AS contained 694 mg flavonoids and FIGURE 3 Mean 6 SEM postprandial serum glucose (A), insulin (B), and plasma total oxidant capacity (C) responses to a high-fat breakfast (50 g fat) and a standard lunch (14 g fat). The smoothies were consumed by volunteers with the breakfast meal only. The vertical line in panels A and B represents the timing of the lunch meal. Two-factor repeated-measures ANOVA was used to assess treatment, time, and treatment-by-time interaction effect. Paired-samples t tests were used to compare incremental AUCs between the açai smoothies relative to the control. (A) Glucose response: treatment effect, P = 0.14; time effect, P , 0.001; time-by-treatment interaction, P = 0.38. (B). Insulin response: treatment effect, P = 0.02; time effect, P , 0.001; time-by-treatment interaction, P = 0.15. (C) Plasma total oxidant capacity: treatment effect, P = 0.85; time effect, P = 0.36; time-bytreatment interaction, P = 0.68. Incremental AUC, P = 0.02.
phenolic acids compared with ,10 mg in the PS. Our approach, which used a whole food as opposed to purified phenolic isolates, does not allow us to fully assess whether it is the polyphenols present in the food mediating the observed response; and we cannot completely exclude the possibility that other known or unknown compounds might be responsible for the biological outcomes. Both acute and chronic dietary interventions with other plant polyphenol-rich foods, such as blueberries (13) , pomegranate juice (25) , dark chocolate (6), and cocoa (14, 26, 27) , induce similar changes in vascular function; and purified flavonoids have also been shown to induce this effect in hypercholesteremic volunteers (28) . We observed peaks in FMD at 2 and 6 h postconsumption of the AS. Rodriguez-Mateos et al. (13) identified similar peaks in postprandial FMD in healthy men who consumed blueberries at 2 and 6 h, and this correlated with peaks in plasma concentrations of phenolic acid metabolites and a reduction in neutrophil NAD(P)H oxidase activity in that study. This time course may reflect the emergence of phenolic metabolites in plasma after small intestinal absorption and later, at 6 h, the liberation of phenolic compounds during colonic fermentation (29) (30) (31) .
The mechanism by which phenolics improve endothelial function is unclear; it is possible that it is related to their wellestablished antioxidant activity (32, 33) . One hypothesis is that phenolics may reduce NAD(P)H oxidase activity and that this may be linked to an increased concentration of nitric oxide via inhibition of superoxide production (34, 35) .
We observed no changes in BP at any time point after AS intake. This is similar to another açai study, which reported no effect on BP after consumption of 100 g açai pulp 2 times/d for 1 mo (36) , and is in line with findings from previous acute interventions with polyphenol-rich foods (13, 37) . However, chronic, or longer term, interventions with polyphenol-rich foods provided to high-risk groups are often shown to be effective at lowering BP (6, 25, (38) (39) (40) (41) .
No differences were observed in postprandial glucose responses between the AS and the carbohydrate-and energymatched control (PS), but a significantly higher insulin response was observed for the AS than for the PS. Zunino (42) and others (7, 43) have argued that phenolics can improve glucose control, although the mechanism has not been elucidated. Findings from studies of other polyphenol-rich foods are not consistent when it comes to their effects on plasma glucose and insulin (7, 8, 30, (43) (44) (45) (46) (47) (48) (49) . Further work is clearly needed to understand this elevated insulin response and to determine whether it may be clinically relevant to glucose control.
We also observed a reduction in total peroxide concentrations in plasma after consumption of the AS, which we included as a measure of acute changes in plasma oxidant capacity. Again, we hypothesized that this is a function of phenolics emerging in plasma. Previously, the consumption of grape polyphenols induced similar effects in pre-and postmenopausal women (50) . In experimental models, oxidative stress is strongly linked to endothelial function and to CVD (51, 52) . Measures of plasma TOC are, however, widely critiqued; and our observation therefore warrants follow-up with the use of different measures, such as the presence of oxidized LDL after a longer term intervention.
A limitation of the present study is that we did not determine and directly correlate polyphenols and their metabolites in plasma or urine in tandem with our FMD measures and nitric oxide, as assessed by Rodriguez-Mateos et al. (13) in an intervention with blueberries. Our study was a short-term acute intervention in overweight middle-aged men, selected as a highrisk group for CVD. We cannot infer the long-term effects of açai consumption on vascular function or rule out physiologic adaptations to the presence of high quantities of açai polyphenols in the diet, which might offset the observed short-term benefits reported here. Future studies might consider chronic study designs, and data are still needed on the effects of açai consumption in other groups.
To our knowledge, this trial is the first well-controlled acute intervention study in humans that shows actual benefits from consumption of açai with the use of a well-validated biomarker of CVD risk as an endpoint. The findings of this double-blind, randomized crossover study are therefore timely and important and suggest that consumption of açai as part of a balanced diet and a healthy lifestyle may improve cardiovascular health, which strongly supports arguments for the health benefits of açai consumption.
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